Showing results (451-460 of 585) with videos related to

Sort By:
Pageof 59
Journal of Clinical Medicine|January 11, 2024
Efficacy and Safety of Vedolizumab in Patients with Inflammatory Bowel Disease in Association with Vedolizumab Drug LevelsEva Hüttemann, Anna Muzalyova, Katharina Gröhl, et al.
Plos One|May 27, 2021
Binding and neutralization of C. difficile toxins A and B by purified clinoptilolite-tuffCarmen Ranftler, Dietmar Nagl, Andreas Sparer, et al.
Molecular Medicine (Cambridge, Mass.)|May 1, 1995
Antiviral drugs from the nucleoside analog family block volume-activated chloride channelsM Gschwentner, A Susanna, E Wöll, et al.
Plos One|January 13, 2017
T Cell Epitope-Containing Domains of Ragweed Amb a 1 and Mugwort Art v 6 Modulate Immunologic Responses in Humans and MiceAna I Sancho, Michael Wallner, Michael Hauser, et al.
Advances in Experimental Medicine and Biology|August 30, 2017
Comparative Analysis of Microbicidal and Anti-inflammatory Properties of Novel Taurine Bromamine Derivatives and Bromamine TM Walczewska, A Peruń, A Białecka, et al.
International Journal of Environmental Research and Public Health|April 3, 2021
Health Care Services Utilization and Health-Related Quality of Life of Syrian Refugees with Post-Traumatic Stress Symptoms in Germany (the Sanadak Trial)Thomas Grochtdreis, Susanne Röhr, Franziska U Jung, et al.
BMC Public Health|October 4, 2022
Knowledge and awareness about and use of iodised salt among students in Germany and GreeceKatharina Heimberg, Annett Martin, Anke Ehlers, et al.
Mycotoxin Research|March 29, 2022
Fungal species and mycotoxins in mouldy spots of grass and maize silages in AustriaFelipe Penagos-Tabares, Ratchaneewan Khiaosa-Ard, Marlene Schmidt, et al.
Journal of Breath Research|January 6, 2015
Breath analysis for in vivo detection of pathogens related to ventilator-associated pneumonia in intensive care patients: a prospective pilot studyWojciech Filipiak, Ronny Beer, Andreas Sponring, et al.
The Journal of Allergy and Clinical Immunology|September 6, 2017
Efficacy and safety of 4 months of sublingual immunotherapy with recombinant Mal d 1 and Bet v 1 in patients with birch pollen-related apple allergyTamar Kinaciyan, Birgit Nagl, Sandra Faustmann, et al.
Pageof 59